JP2020530770A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530770A5 JP2020530770A5 JP2020503056A JP2020503056A JP2020530770A5 JP 2020530770 A5 JP2020530770 A5 JP 2020530770A5 JP 2020503056 A JP2020503056 A JP 2020503056A JP 2020503056 A JP2020503056 A JP 2020503056A JP 2020530770 A5 JP2020530770 A5 JP 2020530770A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding domain
- amino acid
- acid sequence
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 239000002552 dosage form Substances 0.000 claims 13
- 239000012636 effector Substances 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 4
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000000539 dimer Substances 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 2
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 2
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 2
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 2
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 2
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 2
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 230000020411 cell activation Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 201000004404 Neurofibroma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- -1 elixirs Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762535107P | 2017-07-20 | 2017-07-20 | |
| US62/535,107 | 2017-07-20 | ||
| US201762575820P | 2017-10-23 | 2017-10-23 | |
| US62/575,820 | 2017-10-23 | ||
| US201862648072P | 2018-03-26 | 2018-03-26 | |
| US62/648,072 | 2018-03-26 | ||
| PCT/EP2018/069850 WO2019016402A1 (en) | 2017-07-20 | 2018-07-20 | BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530770A JP2020530770A (ja) | 2020-10-29 |
| JP2020530770A5 true JP2020530770A5 (enExample) | 2021-08-26 |
| JP7369113B2 JP7369113B2 (ja) | 2023-10-25 |
Family
ID=63113484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503056A Active JP7369113B2 (ja) | 2017-07-20 | 2018-07-20 | 癌胎児性抗原結合タンパク質、関連する化合物および方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11725060B2 (enExample) |
| EP (1) | EP3655439A1 (enExample) |
| JP (1) | JP7369113B2 (enExample) |
| KR (1) | KR102649757B1 (enExample) |
| CN (1) | CN111148763B (enExample) |
| AU (1) | AU2018304585B2 (enExample) |
| BR (1) | BR112020001180A2 (enExample) |
| CA (1) | CA3070272A1 (enExample) |
| CO (1) | CO2020001654A2 (enExample) |
| IL (1) | IL272103B2 (enExample) |
| MX (1) | MX2020000583A (enExample) |
| NZ (1) | NZ761636A (enExample) |
| PH (1) | PH12020500137A1 (enExample) |
| SG (1) | SG11202000503QA (enExample) |
| WO (1) | WO2019016402A1 (enExample) |
| ZA (1) | ZA202000961B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018071612A2 (pt) | 2016-04-22 | 2019-02-19 | Alligator Bioscience Ab | polipeptídeos biespecíficos inovadores contra cd137 |
| EP3595705A1 (en) * | 2017-03-15 | 2020-01-22 | Oxford BioMedica (UK) Limited | Method |
| US11725060B2 (en) | 2017-07-20 | 2023-08-15 | Aptevo Reserch and Development LLC | Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods |
| MA52152A (fr) | 2018-03-12 | 2021-01-20 | Genmab As | Anticorps |
| MX2022001027A (es) | 2019-07-26 | 2022-04-18 | Abl Bio Inc | Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo. |
| CN118638240A (zh) * | 2019-07-26 | 2024-09-13 | 柳韩洋行 | 抗her2/抗4-1bb双特异性抗体及其用途 |
| MX2022001882A (es) * | 2019-08-12 | 2022-05-30 | Aptevo Res & Development Llc | Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40. |
| US12674001B2 (en) | 2019-09-12 | 2026-07-07 | Genmab A/S | Method of treating cancer by administering an antibody which binds to 5T4 |
| WO2022002063A1 (zh) * | 2020-06-30 | 2022-01-06 | 和铂医药(上海)有限责任公司 | 一种4-1bb结合蛋白及其应用 |
| WO2022183185A1 (en) * | 2021-02-23 | 2022-09-01 | Pandion Operations, Inc. | Pd-1 antibodies, polypeptides and uses thereof |
| US20240262930A1 (en) * | 2021-05-28 | 2024-08-08 | Xyone Therapeutics Inc. | Multi-specific antibody constructs against the muc1-c/extracellular domain (muc1-c/ed) |
| CN122036885B (zh) * | 2026-04-13 | 2026-07-17 | 廊坊天光生物技术有限公司 | 从头设计的癌胚抗原结合蛋白、检测试剂及其应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| DK368882A (da) | 1981-08-25 | 1983-02-26 | Alan John Kingsman | Expessions vektorer |
| US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US4486533A (en) | 1982-09-02 | 1984-12-04 | St. Louis University | Filamentous fungi functional replicating extrachromosomal element |
| US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| US4977092A (en) | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4661454A (en) | 1983-02-28 | 1987-04-28 | Collaborative Research, Inc. | GAL1 yeast promoter linked to non galactokinase gene |
| US5139936A (en) | 1983-02-28 | 1992-08-18 | Collaborative Research, Inc. | Use of the GAL1 yeast promoter |
| US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| CA1280080C (en) | 1984-12-06 | 1991-02-12 | Jacques Oberto | Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5063154A (en) | 1987-06-24 | 1991-11-05 | Whitehead Institute For Biomedical Research | Pheromone - inducible yeast promoter |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US5162228A (en) | 1988-12-28 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Gylceraldehyde-3-phosphate dehydrogenase gene and promoter |
| US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5298418A (en) | 1991-09-16 | 1994-03-29 | Boyce Thompson Institute For Plant Research, Inc. | Cell line isolated from larval midgut tissue of Trichoplusia ni |
| WO1994006463A1 (en) | 1992-09-14 | 1994-03-31 | Pfizer Inc | Immortalized cells and uses therefor |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US5955349A (en) | 1996-08-26 | 1999-09-21 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in Pichia methanolica |
| US5716808A (en) | 1995-11-09 | 1998-02-10 | Zymogenetics, Inc. | Genetic engineering of pichia methanolica |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| CN1230997A (zh) | 1996-07-17 | 1999-10-06 | 津莫吉尼蒂克斯公司 | 甲醇毕赤酵母的转化 |
| US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| ATE411342T1 (de) * | 1999-11-18 | 2008-10-15 | Oxford Biomedica Ltd | Scfv antikörper gegen krankheiten-assoziierte moleküle |
| MXPA02007473A (es) | 2000-02-01 | 2003-09-22 | Tanox Inc | Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40. |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| CA2578131A1 (en) | 2004-09-10 | 2006-03-23 | Wyeth | Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| SG170091A1 (en) | 2006-03-10 | 2011-04-29 | Wyeth Corp | Anti-5t4 antibodies and uses thereof |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| KR20110044991A (ko) | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＮＦ-α 길항제 다-표적 결합 단백질 |
| AU2009298131B2 (en) | 2008-10-02 | 2016-07-14 | Aptevo Research And Development Llc | CD86 antagonist multi-target binding proteins |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| KR101870555B1 (ko) | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
| MX2014003313A (es) | 2011-09-23 | 2014-07-09 | Amgen Res Munich Gmbh | Moleculas de union biespecificas para 5t4 y cd3. |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| MX380176B (es) | 2014-04-07 | 2025-03-12 | Chugai Pharmaceutical Co Ltd | Molecula ligada a antigeno inmunoactivada. |
| US20150307620A1 (en) | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
| CN112546230A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| DK3186284T3 (da) | 2014-08-28 | 2022-05-09 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| WO2016094873A2 (en) * | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| SMT201900702T1 (it) | 2015-01-08 | 2020-01-14 | Genmab As | Agenti agonistici leganti il recettore del tnf |
| WO2016115274A1 (en) | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| US9988454B2 (en) | 2015-05-20 | 2018-06-05 | Immunwork Inc. | Peptide core-based multi-arm linkers for treating central nervous system diseases |
| BR112017024770A2 (pt) * | 2015-05-21 | 2018-07-31 | Alligator Bioscience Ab | polipeptídeos inovadores |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| HK1251480A1 (zh) | 2015-09-21 | 2019-02-01 | Aptevo Research And Development Llc | Cd3结合多肽 |
| BR112018071612A2 (pt) * | 2016-04-22 | 2019-02-19 | Alligator Bioscience Ab | polipeptídeos biespecíficos inovadores contra cd137 |
| BR112019017628A2 (pt) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| US11725060B2 (en) | 2017-07-20 | 2023-08-15 | Aptevo Reserch and Development LLC | Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods |
-
2018
- 2018-07-20 US US16/632,144 patent/US11725060B2/en active Active
- 2018-07-20 KR KR1020207004833A patent/KR102649757B1/ko active Active
- 2018-07-20 AU AU2018304585A patent/AU2018304585B2/en active Active
- 2018-07-20 WO PCT/EP2018/069850 patent/WO2019016402A1/en not_active Ceased
- 2018-07-20 SG SG11202000503QA patent/SG11202000503QA/en unknown
- 2018-07-20 BR BR112020001180-0A patent/BR112020001180A2/pt active Search and Examination
- 2018-07-20 MX MX2020000583A patent/MX2020000583A/es unknown
- 2018-07-20 NZ NZ761636A patent/NZ761636A/en unknown
- 2018-07-20 IL IL272103A patent/IL272103B2/en unknown
- 2018-07-20 EP EP18750355.2A patent/EP3655439A1/en active Pending
- 2018-07-20 CN CN201880060362.6A patent/CN111148763B/zh active Active
- 2018-07-20 CA CA3070272A patent/CA3070272A1/en active Pending
- 2018-07-20 US US16/041,309 patent/US10239949B2/en active Active
- 2018-07-20 JP JP2020503056A patent/JP7369113B2/ja active Active
-
2019
- 2019-02-21 US US16/281,440 patent/US11312786B2/en active Active
-
2020
- 2020-01-20 PH PH12020500137A patent/PH12020500137A1/en unknown
- 2020-02-13 CO CONC2020/0001654A patent/CO2020001654A2/es unknown
- 2020-02-14 ZA ZA2020/00961A patent/ZA202000961B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272103B1 (en) | Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer | |
| JP7273101B2 (ja) | Ｃｄ３８に結合する抗体治療剤 | |
| EP3954707A1 (en) | Protease cleavable bispecific antibodies and uses thereof | |
| RU2019120079A (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2020501531A5 (enExample) | ||
| JP2021534762A5 (enExample) | ||
| JP2022031784A5 (enExample) | ||
| JP2018531000A5 (enExample) | ||
| JP2017530722A5 (enExample) | ||
| DK2921503T3 (en) | Human antibody to human epidermal growth factor receptor and coding gene and its use | |
| CN115397852B (zh) | 工程化抗il-2抗体 | |
| SG185035A1 (en) | Antibodies that bind csf1r | |
| JP2015024994A (ja) | ＤＡＲＰｉｎを含む二重特異キメラ蛋白質 | |
| JP2019531764A5 (enExample) | ||
| CN113874082B (zh) | 结合bcma的抗原结合蛋白 | |
| JP2022512891A5 (enExample) | ||
| WO2019196309A1 (zh) | 抗pd-l1抗体及其用途 | |
| JP2022527173A5 (enExample) | ||
| IL301276A (en) | Novel human antibodies that bind to human CD3-epsilon | |
| WO2023109888A1 (zh) | 抗ang2-vegf双特异性抗体及其用途 | |
| CN103172741B (zh) | 全人源抗egfr抗体 | |
| KR20180010178A (ko) | Jag1에 결합하는 항체 치료제 | |
| CN114075288B (zh) | 抗pd-l2抗体 | |
| CN115885044A (zh) | SIRPγ变体及其融合蛋白 | |
| CN118546255A (zh) | 一种靶向αvβ3和CD47的双功能融合蛋白以及其应用 |